Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Enantiomeric drug development: issues, considerations, and regulatory requirements.

Srinivas NR, Barbhaiya RH, Midha KK.

J Pharm Sci. 2001 Sep;90(9):1205-15. Review. No abstract available.

PMID:
11745774
2.

Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food.

Marathe PH, Arnold ME, Meeker J, Greene DS, Barbhaiya RH.

J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1494-502.

PMID:
11185672
3.

Effect of altered gastric emptying and gastrointestinal motility on metformin absorption.

Marathe PH, Wen Y, Norton J, Greene DS, Barbhaiya RH, Wilding IR.

Br J Clin Pharmacol. 2000 Oct;50(4):325-32.

4.

Disposition of radiolabeled ifetroban in rats, dogs, monkeys, and humans.

Dockens RC, Santone KS, Mitroka JG, Morrison RA, Jemal M, Greene DS, Barbhaiya RH.

Drug Metab Dispos. 2000 Aug;28(8):973-80.

PMID:
10901709
5.

Toxicokinetics of 2',3'-didehydro-3'-deoxythymidine, stavudine (D4T).

Kaul S, Dandekar KA, Schilling BE, Barbhaiya RH.

Drug Metab Dispos. 1999 Jan;27(1):1-12.

PMID:
9884303
6.

In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy.

Marathe PH, Sandefer EP, Kollia GE, Greene DS, Barbhaiya RH, Lipper RA, Page RC, Doll WJ, Ryo UY, Digenis GA.

J Pharmacokinet Biopharm. 1998 Feb;26(1):1-20.

PMID:
9773390
7.

Evaluation of the effect of food on the pharmacokinetics of avitriptan.

Marathe PH, Greene DS, Kollia GD, Barbhaiya RH.

Biopharm Drug Dispos. 1998 Sep;19(6):381-94.

PMID:
9737819
8.

Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers.

Vachharajani NN, Shyu WC, Chando TJ, Everett DW, Greene DS, Barbhaiya RH.

J Clin Pharmacol. 1998 Aug;38(8):702-7.

PMID:
9725545
9.

Biotransformation of irbesartan in man.

Chando TJ, Everett DW, Kahle AD, Starrett AM, Vachharajani N, Shyu WC, Kripalani KJ, Barbhaiya RH.

Drug Metab Dispos. 1998 May;26(5):408-17.

PMID:
9571222
10.

Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers.

Vachharajani NN, Shyu WC, Mantha S, Park JS, Greene DS, Barbhaiya RH.

J Clin Pharmacol. 1998 May;38(5):433-6.

PMID:
9602956
11.

Pharmacokinetic assessment of the sites of first-pass metabolism of BMS-181101, an antidepressant agent, in rats.

Vachharajani NN, Shyu WC, Shah VR, Barbhaiya RH.

J Pharm Pharmacol. 1998 Mar;50(3):275-8.

PMID:
9600718
12.

Assessment of effect of food, gender, and intra-subject variability in the pharmacokinetics of avitriptan.

Marathe PH, Greene DS, Lee JS, Barbhaiya RH.

Biopharm Drug Dispos. 1998 Apr;19(3):153-7.

PMID:
9569997
13.

A pharmacokinetic interaction study of avitriptan and propranolol.

Marathe PH, Greene DS, Kollia GD, Barbhaiya RH.

Clin Pharmacol Ther. 1998 Mar;63(3):367-78.

PMID:
9542480
14.

Pharmacokinetic interaction between butorphanol nasal spray and oral metoclopramide in healthy women.

Vachharajani NN, Shyu WC, Barbhaiya RH.

J Clin Pharmacol. 1997 Oct;37(10):979-85.

PMID:
9505990
15.

The effects of age and gender on the single dose pharmacokinetics of avitriptan administered to healthy volunteers.

Marathe PH, Greene DS, Kollia GD, Barbhaiya RH.

J Clin Pharmacol. 1997 Oct;37(10):937-45.

PMID:
9505985
16.

Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.

Srinivas NR, Shyu WC, Gleason C, Schuster A, Greene DS, Barbhaiya RH.

Clin Pharmacol Ther. 1997 Oct;62(4):408-16.

PMID:
9357392
17.

Clinical pharmacokinetics of nefazodone.

Greene DS, Barbhaiya RH.

Clin Pharmacokinet. 1997 Oct;33(4):260-75. Review.

PMID:
9342502
18.

Lack of effect of food on the steady state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.

Srinivas NR, Shyu WC, Lee J, Greene DS, Barbhaiya RH.

Biopharm Drug Dispos. 1997 Oct;18(7):585-93.

PMID:
9330779
19.
20.

Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat.

Yang Z, Brundage RC, Barbhaiya RH, Sawchuk RJ.

Pharm Res. 1997 Jul;14(7):865-72.

PMID:
9244142
21.

Disposition of [14C]avitriptan in rats and humans.

Marathe PH, Greene DS, Barbhaiya RH.

Drug Metab Dispos. 1997 Jul;25(7):881-8.

PMID:
9224783
22.

The pharmacokinetics of butorphanol and its metabolites at steady state following nasal administration in humans.

Vachharajani NN, Shyu WC, Greene DS, Barbhaiya RH.

Biopharm Drug Dispos. 1997 Apr;18(3):191-202.

PMID:
9113342
24.

Effects of gender, age, and race on the pharmacokinetics of etoposide after intravenous administration of etoposide phosphate in cancer patients.

Kaul S, Srinivas NR, Mummaneni V, Igwemezie LN, Barbhaiya RH.

Semin Oncol. 1996 Dec;23(6 Suppl 13):23-9.

PMID:
8996572
25.

A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients.

Kaul S, Srinivas NR, Igwemezie LN, Barbhaiya RH.

Semin Oncol. 1996 Dec;23(6 Suppl 13):15-22.

PMID:
8996571
26.
27.

Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.

Knupp CA, Hak LJ, Coakley DF, Falk RJ, Wagner BE, Raasch RH, van der Horst CM, Kaul S, Barbhaiya RH, Dukes GE.

Clin Pharmacol Ther. 1996 Nov;60(5):535-42.

PMID:
8941026
28.

Lack of pharmacokinetic interaction between butorphanol nasal spray and cimetidine.

Shyu WC, Barbhaiya RH.

Br J Clin Pharmacol. 1996 Oct;42(4):513-7.

29.

The absolute bioavailability and pharmacokinetics of butorphanol nasal spray in patients with hepatic impairment.

Vachharajani NN, Shyu WC, Garnett WR, Morgenthien EA, Barbhaiya RH.

Clin Pharmacol Ther. 1996 Sep;60(3):283-94.

PMID:
8841151
30.

Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters.

Mummaneni V, Kaul S, Igwemezie LN, Newell DR, Porter D, Thomas H, Calvert AH, Winograd B, Barbhaiya RH.

J Pharmacokinet Biopharm. 1996 Aug;24(4):313-25.

PMID:
9044163
31.

Quantitative determination of butorphanol and its metabolites in human plasma by gas chromatography-electron capture negative-ion chemical ionization mass spectrometry.

Mulvana DE, Duncan GF, Shyu WC, Tay LK, Barbhaiya RH.

J Chromatogr B Biomed Appl. 1996 Jul 12;682(2):289-300.

PMID:
8844422
32.
33.

Pharmacokinetics of butorphanol nasal spray in patients with renal impairment.

Shyu WC, Morgenthien EA, Barbhaiya RH.

Br J Clin Pharmacol. 1996 May;41(5):397-402.

34.
35.

The lack effect of food on the bioavailability of nefazodone tablets.

Dockens RC, Greene DS, Barbhaiya RH.

Biopharm Drug Dispos. 1996 Mar;17(2):135-43.

PMID:
8907720
36.
37.

Bioequivalence of two tablet formulations of nadolol using single and multiple dose data: assessment using stereospecific and nonstereospecific assays.

Srinivas NR, Barr WH, Shyu WC, Mohandoss E, Chow S, Staggers J, Balan G, Belas FJ, Blair IA, Barbhaiya RH.

J Pharm Sci. 1996 Mar;85(3):299-303.

PMID:
8699333
38.

A pharmacokinetic study of intravenous CTLA4Ig, a novel immunosuppressive agent, in mice.

Srinivas NR, Weiner RS, Shyu WC, Calore JD, Tritschler D, Tay LK, Lee JS, Greene DS, Barbhaiya RH.

J Pharm Sci. 1996 Mar;85(3):296-8.

PMID:
8699332
39.
40.

Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol.

Barbhaiya RH, Shukla UA, Greene DS, Breul HP, Midha KK.

J Clin Psychopharmacol. 1996 Feb;16(1):26-34.

PMID:
8834415
41.

A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses.

Barbhaiya RH, Buch AB, Greene DS.

J Clin Psychopharmacol. 1996 Feb;16(1):19-25.

PMID:
8834414
42.

Pharmacokinetics and pharmacodynamics of CTLA4lg (BMS-188667), a novel immunosuppressive agent, in monkeys following multiple doses.

Srinivas NR, Weiner RS, Warner G, Shyu WC, Davidson T, Fadrowski CG, Tay LK, Lee JS, Greene DS, Barbhaiya RH.

J Pharm Sci. 1996 Jan;85(1):1-4.

PMID:
8926572
43.

Pharmacokinetics, absolute bioavailability, and disposition of [14C]nefazodone in humans.

Barbhaiya RH, Dandekar KA, Greene DS.

Drug Metab Dispos. 1996 Jan;24(1):91-5.

PMID:
8825195
44.
45.
46.

Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam.

Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH.

J Clin Psychopharmacol. 1995 Dec;15(6):409-16.

PMID:
8748429
47.

Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam.

Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH.

J Clin Psychopharmacol. 1995 Dec;15(6):399-408.

PMID:
8748428
48.

Pharmacokinetics of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following intravenous and subcutaneous administration to mice.

Srinivas NR, Shyu WC, Weiner RS, Tay LK, Greene DS, Barbhaiya RH.

J Pharm Sci. 1995 Dec;84(12):1488-9. No abstract available.

PMID:
8748333
50.

Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans.

Marathe PH, Salazar DE, Greene DS, Brennan J, Shukla UA, Barbhaiya RH.

Pharm Res. 1995 Nov;12(11):1716-21.

PMID:
8592675

Supplemental Content

Loading ...
Support Center